Lineage-specific canonical and non-canonical activity of EZH2 in advanced prostate cancer subtypes

VB Venkadakrishnan, AG Presser, R Singh, MA Booker… - 2024 - researchsquare.com
Enhancer of zeste homolog 2 (EZH2) is a histone methyltransferase and emerging
therapeutic target that is overexpressed in most castration resistant prostate cancers and …
相关文章

Lineage-specific canonical and non-canonical activity of EZH2 in advanced prostate cancer subtypes

VB Venkadakrishnan, AG Presser, R Singh… - Research … - ncbi.nlm.nih.gov
Enhancer of zeste homolog 2 (EZH2) is a histone methyltransferase and emerging
therapeutic target that is overexpressed in most castration resistant prostate cancers and …

Lineage-specific canonical and non-canonical activity of EZH2 in advanced prostate cancer subtypes.

VB Venkadakrishnan, AG Presser, R Singh… - Research …, 2024 - europepmc.org
Enhancer of zeste homolog 2 (EZH2) is a histone methyltransferase and emerging
therapeutic target that is overexpressed in most castration resistant prostate cancers and …

Lineage-specific canonical and non-canonical activity of EZH2 in advanced prostate cancer subtypes

VB Venkadakrishnan, AG Presser… - Research …, 2024 - pubmed.ncbi.nlm.nih.gov
Enhancer of zeste homolog 2 (EZH2) is a histone methyltransferase and emerging
therapeutic target that is overexpressed in most castration resistant prostate cancers and …

Lineage-specific canonical and non-canonical activity of EZH2 in advanced prostate cancer subtypes

VB Venkadakrishnan, AG Presser, R Singh, MA Booker… - 2024 - europepmc.org
Enhancer of zeste homolog 2 (EZH2) is a histone methyltransferase and emerging
therapeutic target that is overexpressed in most castration resistant prostate cancers and …